DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > Graduate School of Biomedical Sciences > dissertation > dissertation >

Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire

File Description SizeFormat
ISYK919_Nozaki.pdf229.03 kBAdobe PDFView/Open

Title: Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire
Other Titles: 新規質問票NADIQを用いた中枢性尿崩症患者のQOL評価
Authors: 野崎, 彩
Authors (alternative): Nozaki, Aya
Issue Date: 21-Mar-2017
Publisher: Springer
Citation: Nagasaki University (長崎大学), 博士(医学) (2017-03-21)
Abstract: Central diabetes insipidus (CDI) is characterized by polyuria and polydipsia due to a deficiency of vasopressin. Currently, the treatment goal for CDI is improvement of quality of life (QOL) by desmopressin (DDAVP) without developing hyponatremia. However, there is no reliable measure for QOL in CDI patients. We evaluate our original questionnaire for QOL, consisting of 12 questions focusing on polyuria, polydipsia, and DDAVP treatment, in CDI patients who underwent a switch from nasal spray to oral disintegrating tablets of DDAVP. Twenty-five CDI patients under nasal DDAVP treatment, six with newly developed CDI, and 18 healthy individuals without known polyuric/polydipsic disorders as control subjects were enrolled. QOL scores were determined by our questionnaire at the enrollment and 3 months after the start of oral DDAVP treatment and were examined by the Wilcoxon signed-rank test. Eleven questions detected improvement in QOL. The sum of the QOL scores of the eleven questions increased from 29.2 ± 5.6 under nasal to 36.8 ± 4.5 under oral DDAVP (p < 0.001). There were no clinically relevant changes in serum levels of Na. After eliminating two questions about DDAVP treatment, the sum of QOL scores was 15.3 ± 6.5 in untreated CDI patients, 24.4 ± 5.2 in those with nasal treatment, 28.9 ± 4.9 in those with oral DDAVP, and 29.5 ± 3.6 in healthy controls. The difference among groups was significant (p < 0.05 in Steel–Dwass test) except between patients treated with oral DDAVP and healthy controls. Our questionnaire can be used to accurately assess QOL in CDI patients.
Description: 長崎大学学位論文 学位記番号:博(医歯薬)甲第919号 学位授与年月日:平成29年3月21日 / Author: Aya Nozaki, Takao Ando, Satoru Akazawa, Tsuyoshi Satoh, Ikuko Sagara, Ichiro Horie, Misa Imaizumi, Toshiro Usa, Robert T. Yanagisawa, Atsushi Kawakami / Citation: Endocrine, 51(1), pp.140-147; 2016
Keywords: Diabetes insipidus / Quality of life / Questionnaire / Desmopressin
URI: http://hdl.handle.net/10069/37092
ISSN: 1355008X
DOI: 10.1007/s12020-015-0637-3
Rights: © Springer Science+Business Media New York 2015 / The final publication is available at link.springer.com
Type: Thesis or Dissertation
Text Version: ETD
Appears in Collections:dissertation

Citable URI : http://hdl.handle.net/10069/37092

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace